脓毒症心肌病患者cTnI IMA和CK-MB浓度水平变化及与预后的关系

doi:10.3969/j.issn.1006-6233.2018.06.016

Abstract
Figure/Table
References
Related Citation (10)

Download: PDF (1325 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate changes in levels of cardiac troponin I (cTnI), ischemia modified albumin (IMA) and creatine kinase isoenzyme (CK-MB) in patients with septic cardiomyopathy and their relationship with the prognosis. Methods: The clinical data of 90 patients with septic cardiomyopathy who were admitted to the hospital from February 2011 to February 2016 were retrospectively analyzed. The patients were divided into the survival group and the death group according to the survival within 1 month, and the general datawere compared between the two groups. Levels of cTnI, IMA and CK-MB in the two groups were detected at different time points (the day of diagnosis, the6th and12thday). The correlation between levels of cTnI, IMA and CK-MB in patients with septic cardiomyopathy and the prognosis was analyzed. Results: 51 cases survived and 39 died among the 90 patients within 1 month. The APACHE II score, levels of cTnI, IMA and CK-MB in the survival group were significantly lower than those in the death group (P < 0.05). Levels of cTnI, IMA and CK-MB in the survival group on the day of confirmed diagnosis, on the 6th and 12th days were significantly lower than those in the death group (P < 0.05). Logistic regression analysis showed that increased cTnI, IMA and CK-MB were high risk factors influencing the prognosis of patients with septic cardiomyopathy. Conclusion: Levels of cTnI, IMA and CK-MB are obviously higher in patients with septic cardiomyopathy. The increased cTnI, IMA and CK-MB have significant effect on the prognosis of patients with septic cardiomyopathy.

Key words： Septic cardiomyopathy CTnI IMA CK-MB Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LUO Jiaqing

Cite this article:

LUO Jiaqing. Changes of cTnI, IMA and CK-MB levels in Patients with Septic Cardiomyopathy and their Relationship between the levels and Prognosis[J]. HeBei Med, 2018, 24(6): 943-946.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.06.016 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I6/943

[1] 孙杰,张小坤,付素珍,等.持续性肾脏替代治疗联合血必净对脓毒症患者炎症反应水平、免疫状态及疾病严重程度的影响[J].广东医学,2015,16(3):387~391.
[2] 王勇涛.脓毒症心肌病发病机制的探讨[J].中国急救医学,2016,36(2):120~125.
[3] 薄禄龙,卞金俊,邓小明.2016年脓毒症最新定义与诊断标准:回归本质重新出发[J].中华麻醉学杂志,2016,36(3):259~262.
[4] Jean-Charles P Y,Du J,Li Y,et al.Abstract 843:Restrictive Cardiomyopathy Linked cTnI Mutation(K178E)Causes Severe Heart Failure and Early Mortality[J].Circulation,2008,118(18):S623.
[5] 曹彦,刘智玲,韩小彤.肌钙蛋白-I、缺血修饰白蛋白对脓毒症心肌损伤患者预后评估的价值[J].中国公共卫生,2015,18(A03):25~27.
[6] Hobai I A,Edgecomb J,Labarge K,et al.Dysregulation of intracellular calcium transporters in animal models of sepsis induced cardiomyopathy[J].Shock,2015,43(1):3.
[7] 刘长智,朱瑞秋,周柱江,等.ECMO治疗脓毒症心肌病合并心源性休克[J].中华危重病急救医学,2017,29(12):1140~1143.
[8] 胡甜甜,赵光举,洪广亮,等.心肌肌钙蛋白Ⅰ独立预测严重脓毒症及感染性休克患者死亡率的价值研究[J].中国急救医学,2016,36(4):294~298.
[9] 易梦秋,余旻.脓毒症导致多器官功能障碍的发病机制[J].实用医学杂志,2016,32(20):3451~3454.
[10] 赵凯.脓毒血症患者早期血清心肌肌钙蛋白Ⅰ、肌酸激酶同工酶的变化及临床意义[D].石河子大学,2015.
[11] 黄静.脓毒症患儿心肌损伤的临床研究[D].重庆医科大学,2015.
[12] 于海侠,周景霞,任长安,等.心肺复苏患者血清GDF-15、NT-proBNP、cTnI水平变化的临床意义及其与近期预后的关系[J].中国动脉硬化杂志,2017,25(3):269~273.
[13] 王勇,陈伟.cTnI与CK-MB联合检测在脓毒症患者中的应用价值研究[J].国际检验医学杂志,2017,38(12):1648~1650.
[14] 陈锋,宋海洋,林庆明,等.心肺复苏患者缺血修饰白蛋白的变化及意义[J].中华急诊医学杂志,2015,24(2):183~187.